UBS Sticks to Their Hold Rating for Stryker (SYK)
In a report released today, Danielle Antalffy from UBS maintained a Hold rating on Stryker, with a price target of $400.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Antalffy is a 4-star analyst with an average return of 2.7% and a 49.90% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Inspire Medical Systems, and Insulet.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stryker with a $429.26 average price target.
Based on Stryker’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.17 billion and a net profit of $849 million. In comparison, last year the company earned a revenue of $6.44 billion and had a net profit of $546 million
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year. Earlier this month, Ronda Stryker, a Director at SYK sold 500,000.00 shares for a total of $181,717,233.87.
Read More on SYK:
Disclaimer & DisclosureReport an Issue
- Stryker price target raised to $400 from $386 at UBS
- Walmart downgraded, Etsy upgraded: Wall Street’s top analyst calls
- Stryker initiated with an Outperform at William Blair
- Stryker: Expanding Breast Reconstruction Leadership Warrants Premium Valuation and Buy Rating
- Stryker price target raised to $469 from $462 at Barclays
